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z Evidence summary
Our literature search failed to find 
any randomized controlled trials compar-
ing diagnostic tests for HSV-2 infection 
among asymptomatic populations. Data 
from cross-sectional studies, however, are 
available. 
Glycoprotein G ELISA  
has better specificity
Using the Western blot technique as 
the gold standard, a total of 158 serum 
samples from patients with either HSV-1 
or HSV-2 infection—without mention of 
symptomatology—were used to compare 
What’s the best test  
for HSV-2 after exposure?
  
enzyme-linked	immunosorbent	assay		
(elIsa)	tests	based	on	herpes	simplex	virus	
2’s	(hsv-2)	glycoprotein	G	have	demon-
strated	high	sensitivity	and	specificity	in	
determining	seropositivity	for	hsv-2	anti-
bodies	(strength	of	recommendation	[sor]:	
C,	based	on	cross-sectional	studies).	
elIsa	tests	not	based	on	glycoprotein	
G	are	also	highly	sensitive,	but	they	are	less	
specific	for	hsv-2	and	are	prone	to	false-
positive	results	because	of	cross-reactivity	
with	hsv-1	antibodies	(sor:	C,	based	on	
cross-sectional	studies).	
random	anogenital	cultures	are	not	
sensitive	for	diagnosing	hsv-2	infection	
(TAbLE)	(sor:	B,	based	on	extrapolation	
from	a	well-designed	prospective	cohort	
study).	No	studies	have	found	patient-	
oriented	benefits	to	testing	asymptomatic	
patients	for	hsv-2	infection.
Consider offering these tests to patients  
at high risk of coinfection with HSV
an	estimated	1.6	million	new	cases	of	geni-
tal	herpes	are	diagnosed	annually.	The	viral	
shedding	among	asymptomatic	patients	
poses	a	great	challenge	in	controlling	its	
transmission.	older	methods	of	detecting	
hsv	infection	by	non–glycoprotein	G-based	
elIsa	tests	are	nonspecific	and	do	not	dif-
ferentiate	between	hsv-1	and	hsv-2.	The	
newer	serologic	tests	that	detect	antibod-
ies	to	hsv	glycoproteins	G1	and	G2	are	
available	for	rapid	detection	and	typing	of	
genital	herpes.	sensitivity	and	specificity	of	
these	tests	are	also	higher	than	older	tests.	
although	us	Preventive	services	Task	
Force	(usPsTF)	guidelines	do	not	recom-
mend	routine	screening	of	all	patients	
for	hsv,	it’s	important	that	you	consider	
offering	these	tests	to	patients	at	high	risk	
of	coinfection	with	hsv,	such	as	those	who	
are	hIv-positive.	Good-quality	evidence	
demonstrates	that	systemic	antiviral	
therapy	along	with	condom	use	effectively	
reduces	the	viral	shedding	and	therefore	re-
duces	the	risk	of	genital	hsv	transmission.
Manjula Julka, MD
university	of	Texas	southwestern,	Dallas
Evidence-based answer
Clinical commentary
No studies found 
patient-oriented 
benefits to testing  
asymptomatic  
patients for HSV-2
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Summary of HSV test characteristics
TEST Sn (%) SP (%) lr+  CoST (EST.) TiME To rESulT
Genital culture3	 5*	 100	 Na†	 $90	 24	hours
Western blot1,6	 100	 100	 >99‡	 $104	 2	weeks
Glycoprotein G EliSa1,6	 90–100	 90–100	 19‡	 $4–$20	 1–2	weeks
non–glycoprotein G EliSa1,6	 95–100	 60–85	 3.5‡	 Not	available	 Not	available
*	calculation	using	development	of	symptoms	as	gold	standard.
†	specificity=100%,	so	likelihood	ratio	=	infinity	and	positive	predictive	value	=	1.
‡	lr	calculated	based	on	median	sensitivity	and	specificity	from	sources	cited	in	table.
sN,	sensitivity;	sP,	specificity;	lr+,	positive	likelihood	ratio;	elIsa,	enzyme-linked	immunosorbent	assay.
t a b l e
the performance of several commercially 
available ELISA assays.1 The glycopro-
tein G and non–glycoprotein G ELISA 
tests were both found to have sensitivities 
>90%, but the non–glycoprotein G ELISA 
tests had specificities under 90%. 
In 47% to 82% of the samples tested 
with non–glycoprotein G ELISA, there 
was cross-reactivity between HSV-1 and 
HSV-2 antibodies.1 The College of Ameri-
can Pathologists found that 46% to 84% 
of laboratories using non–glycoprotein G 
ELISA tests incorrectly identified an HSV-
1 sample as being HSV-2. All laboratories 
reporting use of glycoprotein G ELISA 
tests correctly identified the sample as 
containing only HSV-1 antibodies.2 Nei-
ther study included controls, delineated 
symptom status, or measured patient- 
oriented outcomes.
Genital culture has poor sensitivity
A prospective cohort study compared the 
viral shedding by Western blot among 
52 asymptomatic seropositive patients 
with 90 seropositive and symptomatic 
patients.3 Daily genital swabs were done 
for 3 months for each patient. The asymp-
tomatic individuals had HSV-2 positive 
cultures on 3% of culture days.3 Genital 
culture appears to have a very poor sensi-
tivity (5%) for diagnosis of HSV-2 infec-
tion among asymptomatic individuals. 
We found no studies that measured 
patient-oriented harms or benefits arising 
from testing asymptomatic individuals for 
HSV-2 infection.
Recommendations from others
The USPSTF recommends against rou-
tine serological screening for HSV in as-
ymptomatic adolescents and adults (D 
recommendation, fair or good evidence 
that the service is ineffective or that the 
harms outweigh the benefits).4 The Cal-
ifornia Sexually Transmitted Diseases 
Controllers Association recommends 
that serologic testing is likely to ben-
efit HIV-infected patients, those whose 
sexual partners have genital herpes, and 
those at high risk of STDs motivated to 
reduce their sexual risk behavior.5 n
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